Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast

NCT00082667 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT00082667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00082667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2002
Completion date
June 30, 2005
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer